Oncolytic virotherapy as immunotherapy

Alan, Melcher; Kevin, Harrington; Richard, Vile

Found an issue? Give us feedback

Sciencearrow_drop_down

Science

Article . 2021 . Peer-reviewed

Data sources: Crossref

Science

Article . 2021

Data sources: Europe PubMed Central

Oncolytic virotherapy as immunotherapy

descriptionPublicationkeyboard_double_arrow_right Article 10 Dec 2021 English Publisher:American Association for the Advancement of Science (AAAS)Journal:Science, volume 374, pages 1,325-1,326 (issn: 0036-8075, eissn: 1095-9203,

Copyright policy )

Authors: Alan, Melcher; Kevin, Harrington; Richard, Vile;

doi: 10.1126/science.abk3436

pmid: 34882456

pmc: PMC8961675

Oncolytic virotherapy as immunotherapy

- Summary
- Subjects
- Metrics

Abstract

Recognizing immune responses to oncolytic virotherapy opens the way for new combinations

Related Organizations

Mayo Clinic
United States
Mayo Clinic
United States
Institute of Cancer Research
United Kingdom
Mayo Clinic
United States

Keywords

Oncolytic Virotherapy, Oncolytic Viruses, Antineoplastic Agents, Immunological, Neoplasms, Animals, Humans, Immunotherapy, Combined Modality Therapy, Randomized Controlled Trials as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	111
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%